MERLIN researcher Steve Elliman of Orbsen Therapeutics presented at the 8th Annual UK MSC meeting hosted by REMEDI in Galway 29 – 30 Oct, 2014. To read more about the conference, and to see a list of the other speakers, click here.
A new page dedicated to related publications has now gone live on the MERLIN site. This page can be accessed by following this link, and it will be updated throughout the project.
MERLIN recently received coverage on the Primary Sclerosing Cholangitis Support website.
PSC Support is
the UK charity dedicated to helping people affected by Primary Sclerosing Cholangitis (PSC). PSC Support is run by a small team of volunteers, totally funded from charitable donations, and here to help anyone affected by Primary Sclerosing Cholangitis.
Our objectives are to:
- provide information and support to those affected by PSC.
- work with partners to promote awareness of PSC, current research and the need for organ donation.
- support PSC-related medical practitioners and researchers by:
- giving PSC patients access to the latest relevant medical information to promote patient participation in essential trials;
- providing grants towards projects that have specific target outcomes.
- develop effective partnerships between PSC Support and medical practitioners, researchers, policy makers and people affected by PSC.
You can find out more about their organisation here.
The Irish Times covered the MERLIN Project on April 22nd, 2014, in an article titled “Orbsen Therapeutics to take part in €6m liver disease clinical trial.”
Orbsen Therapeutics, a spin-out from NUI Galway’s Regenerative Medicine Institute (Remedi) has announced plans to partner with the University of Birmingham in a €6 million project to fight liver disease.
The stem cell research company, which was founded by Prof Frank Barry and Prof Tom O’Brien in 2006, will collaborate with the university on an EU FP7-funded project known by as Merlin (MEsynchymal stem cells to Reduce Liver INflammation). The project, which is led by Prof Phil Newsome, will advance Orbsen’s proprietary cell therapy to a Phase 2a clinical trial.
Please read the rest of the article here.
MERLIN partners meet in Birmingham, UK, on 10-11 February, 2014 to initiate the project.
The MERLIN project website is now launched. This website will support individuals trying to find out more about the project, and will provide both the public and other researchers with information about our plans, hypotheses, work and results.
- RT @autostem2020: Just out- the @autostem2020 Summer 2018 newsletter! Research & development updates, our new publications list and outreac… Time ago 2 Days via Twitter for iPhone
- Some hard numbers on science’s leadership problems t.co/zX02s0Tdrx @nature Time ago 4 Days via Twitter Web Client
- This project has received funding from the European Union’s Seventh Framework Programme for research, technological… t.co/RD5wxxOB55 Time ago 4 Days via Twitter Web Client
Follow @fp7merlin on twitter.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602363. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.